.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,696,249

« Back to Dashboard

Details for Patent: 5,696,249

Title: Nucleic acid ligands
Abstract:A new class of nucleic acid compounds, referred to as nucleic acid ligands, have been shown to exist that have a specific binding affinity for three dimensional molecular targets. In a preferred embodiment the ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified for further partitioning.
Inventor(s): Gold; Larry (Boulder, CO), Tuerk; Craig (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Mar 24, 1995
Application Number:08/409,442
Claims:1. A nucleic acid ligand comprised of a non-naturally occurring nucleic acid having a specific binding affinity for a target molecule, such target molecule being a three dimensional chemical structure other than a polynucleotide that binds to said nucleic acid ligand through a mechanism which predominantly depends on Watson/Crick base pairing or triple helix binding, wherein said nucleic acid ligand is not a nucleic acid having the known physiological function of being bound by the target molecule obtained by the process of identifying a nucleic acid ligand of a target from a candidate mixture of nucleic acids comprised of nucleic acids each having a region of randomized sequence, said process comprising:

(a) contacting the candidate mixture with the target molecule, wherein nucleic acids having an increased affinity to the target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

(b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

(c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids, whereby a nucleic acid ligand of the target compound may be identified.

2. The nucleic acid ligand of claim 1 wherein said target molecule is a protein.

3. The nucleic acid ligand of claim 1 wherein said nucleic acid ligand is selected from the group consisting of single-stranded RNA, double-stranded RNA, single-stranded DNA and double-stranded DNA.

4. The nucleic acid ligand of claim 1 wherein said nucleic acid ligand is single-stranded.

5. The nucleic acid ligand of claim 4 wherein said nucleic acid ligand is RNA.

6. The nucleic acid ligand of claim 4 wherein said nucleic acid ligand is DNA.

7. The nucleic acid ligand of claim 1 wherein said nucleic acid ligand is double-stranded.

8. The nucleic acid ligand of claim 7 wherein said nucleic acid ligand is RNA.

9. The nucleic acid ligand of claim 7 wherein said nucleic acid ligand is DNA.

10. The nucleic acid ligand of claim 1, wherein said candidate mixture is prepared by synthesis from a template comprising a region of conserved sequence and a region of randomized and/or biased sequence.

11. The nucleic acid of claim 1 wherein said candidate mixture comprises nucleic acids each comprising a region of conserved sequence and a region of randomized sequence.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc